tetano
Editor, Senior Moderator
Biomed Res Int
. 2023 Oct 26:2023:5705076.
doi: 10.1155/2023/5705076. eCollection 2023. Intronic Variants of the Angiotensin-Converting Enzyme 2 Gene Modulate Plasma ACE2 Levels and Possibly Confer Protection against Severe COVID-19
Rubaiat Ahmed[SUP] 1 [/SUP], Abdullah Al Saba[SUP] 1 [/SUP], Anik Paul[SUP] 1 [/SUP], Jasmin Nur[SUP] 2 [/SUP], Md Sohrab Alam[SUP] 2 [/SUP], Sajib Chakraborty[SUP] 1 [/SUP], Md Zakir Hossain Howlader[SUP] 3 [/SUP], Laila N Islam[SUP] 1 [/SUP], A H M Nurun Nabi[SUP] 1 [/SUP]
Affiliations
Membrane-bound angiotensin-converting enzyme 2 (ACE2) receptor acts as the entry point for the novel coronavirus, SARS-CoV-2. Polymorphisms in the ACE2 gene may alter viral binding, regulate the expression of ACE2, and thus, affect disease severity. In this study, 68 COVID-19 patients with varying degrees of severity and 40 healthy controls were enrolled. The genetic landscape of the ACE2 gene was explored by whole exome sequencing of 29 individuals, and specific regions of ACE2 were analyzed for the rest of the participants via PCR, followed by barcode-tagged sequencing. The mean soluble ACE2 level in the plasma of healthy controls and patients did not vary significantly but was higher in the patient group (3.77 ± 1.55 ng/mL vs. 3.94 ± 1.42 ng/mL). Analysis of exon 1, exon 2, and exon 8 of the ACE2 gene revealed that these regions are highly conserved in our population. Investigation of exon 11 and its flanking intronic region revealed that deletions in a stretch of 18T nucleotides in the noncoding region significantly decrease ACE2 levels in plasma, as individuals harboring wild-type variants had higher plasma ACE2 levels compared to those harboring T1del, T2del, and T3del variants. However, the intronic variants were not found to be significantly associated with disease severity.
. 2023 Oct 26:2023:5705076.
doi: 10.1155/2023/5705076. eCollection 2023. Intronic Variants of the Angiotensin-Converting Enzyme 2 Gene Modulate Plasma ACE2 Levels and Possibly Confer Protection against Severe COVID-19
Rubaiat Ahmed[SUP] 1 [/SUP], Abdullah Al Saba[SUP] 1 [/SUP], Anik Paul[SUP] 1 [/SUP], Jasmin Nur[SUP] 2 [/SUP], Md Sohrab Alam[SUP] 2 [/SUP], Sajib Chakraborty[SUP] 1 [/SUP], Md Zakir Hossain Howlader[SUP] 3 [/SUP], Laila N Islam[SUP] 1 [/SUP], A H M Nurun Nabi[SUP] 1 [/SUP]
Affiliations
- PMID: 37929242
- PMCID: PMC10622595
- DOI: 10.1155/2023/5705076
Membrane-bound angiotensin-converting enzyme 2 (ACE2) receptor acts as the entry point for the novel coronavirus, SARS-CoV-2. Polymorphisms in the ACE2 gene may alter viral binding, regulate the expression of ACE2, and thus, affect disease severity. In this study, 68 COVID-19 patients with varying degrees of severity and 40 healthy controls were enrolled. The genetic landscape of the ACE2 gene was explored by whole exome sequencing of 29 individuals, and specific regions of ACE2 were analyzed for the rest of the participants via PCR, followed by barcode-tagged sequencing. The mean soluble ACE2 level in the plasma of healthy controls and patients did not vary significantly but was higher in the patient group (3.77 ± 1.55 ng/mL vs. 3.94 ± 1.42 ng/mL). Analysis of exon 1, exon 2, and exon 8 of the ACE2 gene revealed that these regions are highly conserved in our population. Investigation of exon 11 and its flanking intronic region revealed that deletions in a stretch of 18T nucleotides in the noncoding region significantly decrease ACE2 levels in plasma, as individuals harboring wild-type variants had higher plasma ACE2 levels compared to those harboring T1del, T2del, and T3del variants. However, the intronic variants were not found to be significantly associated with disease severity.